Mankind Pharma has completed the transaction to acquire 100% stake in Bharat Serums and Vaccines (BSV), for a purchase consideration of Rs 13,768 crore. This strategic move marks a significant leap for Mankind Pharma, positioning it as a market leader in the Indian women's health and fertility drug market alongside access to other high entry barrier products in critical care segment with established complex R&D tech platforms.
BSV, with over five decades of leadership in biopharmaceuticals, has developed recombinant and niche biologic products in-house, demonstrating its strong R&D capabilities and boasts of a robust branded product portfolio across Women's Health, Fertility, Critical Care and Immunoglobulins, with a few of its marque brands enjoying a strong leadership position. BSV’s R&D tech platforms will bolster Mankind’s presence in highly complex innovative recombinant, biologics, immunoglobulins and complex delivery products and pipeline. BSV’s established domestic product portfolio offers huge scalability potential through strong registration velocity through niche filings across international markets.
Mankind Pharma is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1808.50 |
Dr. Reddys Lab | 1342.45 |
Cipla | 1472.45 |
Lupin | 2147.55 |
Zydus Lifesciences | 973.90 |
View more.. |